Delving into the Latest Updates on Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd with Synapse

Overview

Tags

Immune System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

To evaluate the change in glycated haemoglobin (HbA1c) from baseline after 24 weeks of insulin enteric-coated capsules combined with oral hypoglycemic drugs in patients with type 2 diabetes who were inadequately controlled with oral hypoglycemic drugs, compared with placebo combined with oral hypoglycemic drugs.

Start Date15 Apr 2020

Sponsor / Collaborator

Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd

[+1]

100 Clinical Results associated with Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd

Login to view more data

0 Patents (Medical) associated with Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd

Login to view more data

100 Deals associated with Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd

Login to view more data

100 Translational Medicine associated with Beijing Representative Office Of Hong Kong Fushi Bioengineering Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data